Mayfair Gold wins Ontario fast-track permitting status for Fenn-Gib as C$310m financing plans advance
Read More Pharma Industry News Revolution Medicines’ Zoldonrasib demonstrates early antitumor potential in kras g12d mutant lung cancer at AACR 2025 Find out how Revolution Medicines’ new data on zoldonrasib could reshape KRAS G12D mutant lung cancer treatment strategies. byPallavi MadhirajuApril 28, 2025